8-K: Replimune Presents RP1 Data to FDA Advisory Committee

Replimune Group, Inc. presented data on RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma to the FDA's Advisory Committee.

Summary

• Replimune Group, Inc. presented its Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab to the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee on July 30, 2026.
• The presentation focused on the efficacy and safety of RP1 plus nivolumab for adults with unresectable advanced cutaneous melanoma who have progressed on anti-PD-1 therapy.
• The IGNYTE Phase 2 trial demonstrated an Overall Response Rate (ORR) of 33.6% (95% CI: 25.8, 42.0) with a median Duration of Response (DoR) of 24.8 months.
• The combination therapy showed a favorable benefit-risk profile, with reviewers recommending accelerated approval.
• The company highlighted the dual mechanism of action of RP1, which drives both local and systemic anti-tumor immune responses.
• Safety data indicated that most adverse events were Grade 1 or 2, with no treatment-related Grade 5 events reported in the IGNYTE trial.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the company is presenting compelling efficacy data to the FDA for a critical indication, with FDA reviewers recommending accelerated approval. However, the reliance on single-arm data and the ongoing confirmatory trial introduce some uncertainty.

Positives

• The IGNYTE trial showed a substantial Overall Response Rate (ORR) of 33.6% in patients with advanced melanoma who progressed on anti-PD-1 therapy.
• The median Duration of Response (DoR) was a durable 24.8 months, indicating long-lasting benefits.
• The combination of RP1 and nivolumab demonstrated a favorable benefit-risk profile, leading to a recommendation for accelerated approval by FDA reviewers.
• RP1's dual mechanism of action, stimulating both local and systemic immune responses, provides a strong biological rationale for its efficacy.
• The safety profile was generally well-tolerated, with the majority of adverse events being Grade 1 or 2.
• The treatment addresses a significant unmet need for patients with advanced melanoma who have limited options after progressing on prior therapies.

Negatives

• The FDA reviewers acknowledged potential biases in the single-arm IGNYTE trial, such as patient selection bias, inherent to such study designs.
• While the ORR was 33.6%, the FDA's initial analysis, using a different RECIST 1.1 application, resulted in a lower ORR of 15.7%.
• The IGNYTE trial is a single-arm study, and a randomized confirmatory trial (IGNYTE-3) is ongoing with OS data expected in 2030.
• There were 12 reported deaths among patients with adverse events considered possibly related by the FDA in a pooled safety analysis (N=335).

Risks

• The primary efficacy data is based on a single-arm trial, necessitating the ongoing IGNYTE-3 randomized confirmatory trial.
• Potential patient selection bias in single-arm trials is a recognized concern.
• The long-term survival benefit (OS) from the IGNYTE-3 trial is not expected until 2030.
• While generally well-tolerated, there were reported deaths in a pooled safety analysis that require careful monitoring.

Future Outlook

The company is awaiting a decision on its BLA resubmission for RP1 in combination with nivolumab. A randomized confirmatory trial (IGNYTE-3) is ongoing, with overall survival data expected in 2030.

Management Comments

• The reviewers acknowledge that the clinical benefit of VO in combination with nivolumab is based on results from a single arm trial with inherited biases including potential patient selection bias, like all single arm trials.
• However, with over 30 clinical information requests including 27 efficacy related clinical information requests with over 136 questions, the reviewers did not find any study conduct or data integrity issues.
• The IGNYTE trial (RPL-001-16) Phase 2 portion is an adequate and well-controlled trial which provides substantial evidence of effectiveness.
• Based on the IGNYTE trial results, a comprehensive literature review, the life-threatening condition of the intended patient population, the absence of treatment with proven clinical benefit in the standard of care setting, and the precedent cases using durable ORR to support drug approvals in this population, the reviewers conclude that the efficacy and safety results from the IGNYTE trial have demonstrated substantial evidence of effectiveness of VO.
• The benefits of VO, used in combination with nivolumab, outweigh risks, representing an improvement over standard of care.
• The benefit over risk profile of VO in combination with nivolumab is superior to lifileucel treatment which is a multi-component regimen... that is associated with high risks.
• Therefore, the reviewers recommend for accelerated approval of VO, used in combinations with nivolumab, for adult patients with confirmed disease progression on anti-PD-1 based therapy.

Industry Context

StockSavvy.ai notes that the presentation to the FDA Advisory Committee is a critical step in the regulatory approval process for Replimune's RP1. The data presented addresses the significant unmet need in advanced melanoma, particularly for patients who have exhausted existing anti-PD-1 therapies. The discussion around RECIST 1.1 application and the use of single-arm trial data highlights common challenges in the oncology drug approval landscape, where innovative therapies often face scrutiny regarding trial design and interpretation of efficacy.

Comparison to Industry Standards

• The ORR of 33.6% for RP1 + Nivolumab in the IGNYTE study is significantly higher than the expected 5-7% ORR for further anti-PD-1 monotherapy in patients who have progressed on prior anti-PD-1 treatment.
• Compared to Lifileucel (AMTAGVI) + IL-2, which has an ORR of 31.5% and a 7.5% treatment-related mortality rate, RP1 + Nivolumab shows a comparable ORR with a generally better safety profile, particularly regarding Grade 5 events.
• The ORR of 33.6% for RP1 + Nivolumab is also higher than the 9-12% ORR observed with Nivolumab + Relatlimab (Opdualag) in a similar patient population (RELATIVITY-020 trial).
• The median DoR of 24.8 months for RP1 + Nivolumab is notably durable, exceeding the typical response durations seen with other salvage therapies in this setting.

Stakeholder Impact

• Shareholders: Potential positive impact on stock price if BLA is approved, reflecting the value of a new treatment option for advanced melanoma.
• Patients: Access to a potentially more effective treatment option for advanced melanoma who have exhausted current therapies.
• Healthcare Providers: Introduction of a new therapeutic option to manage a difficult-to-treat patient population.
• FDA: Continued engagement in the regulatory review process for novel therapies.

Next Steps

• Await FDA decision on the BLA resubmission for RP1 in combination with nivolumab.
• Continue the IGNYTE-3 randomized confirmatory trial.
• Analyze overall survival data from IGNYTE-3, expected in 2030.

Key Dates

Recommendation

The presentation to the FDA Advisory Committee is a positive step, with FDA reviewers recommending accelerated approval based on strong efficacy data. However, the reliance on single-arm trial data and the need for a confirmatory trial with long-term survival data expected in 2030 introduce significant uncertainty. While the potential for approval is high, the long-term outlook and competitive landscape warrant a cautious 'hold' stance until further data and regulatory decisions are finalized.

Keywords

vusolimogene oderparepvec, RP1, nivolumab, advanced melanoma, cutaneous melanoma, oncolytic immunotherapy, FDA, BLA